Burning hepatic fat: Therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease

Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

(2010) Z. M. YOUNOSSI   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics

(2010) Arnoldo Riquelme et al.   LIVER INTERNATIONAL

Review article: diagnosis and treatment of non-alcoholic fatty liver disease

(2008) M. K. OH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Association Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: A First Message Should Pass

(2008) Antonio Picardi et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Selective thyromimetics for atherosclerosis and dyslipidaemia: another old target making progress

(2008) Keith Suckling   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Thyroid hormone (T3) and TRβ agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats

(2008) Andrea Perra et al.   FASEB JOURNAL

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

(2008) Guruprasad P. Aithal et al.   GASTROENTEROLOGY

Non-alcoholic fatty liver disease: The mist gradually clears

(2008) Nimantha Mark Wilfred de Alwis et al.   JOURNAL OF HEPATOLOGY

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

(2008) Stefano Romeo et al.   NATURE GENETICS

Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis

(2008) Fabio Marra et al.   TRENDS IN MOLECULAR MEDICINE